According to a new Datamonitor report, cash-rich drugmakers are poised to take
advantage of the credit crunch, in part because they didn’t
overdose on the cheap debt that has trapped so many companies now that credit
has dried up. …
This $62 million settlement is dwarfed in comparison with previous Zyprexa
deals, including a $1 billion resolution of several thousand patient-safety
claims. …